Inhibikase Therapeutics, Inc.
NASDAQ:IKTBiotechnology
Healthcare
$1.30 +3.57%
+$0.06 today
- Market cap
- $182.35M
- Beta
- 0.97
- P/E (TTM)
- -3.4
- EPS (TTM)
- -$0.52
52W Low $1.33High $2.26
Volume 0.50M
Average 1.03M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$27.79M
FY 2025 · Annual
Investing Cash Flow
$2.05M
FY 2025 · Annual
Financing Cash Flow
$108.46M
FY 2025 · Annual
+4.8% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (14.79M) | (18.05M) | (19.03M) | (27.52M) | (48.26M) |
| Depreciation & Amortization | 0 | 6.72K | 177.4K | 26.27K | 60.5K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 1.53M | 458.15K | 500.15K | 8.14M | 15.31M |
| Change in Working Capital | (1.76M) | 171.18K | 234.76K | 204.93K | 55.93K |
| Accounts Receivables | (110.14K) | 70.26K | 39.88K | 0 | 0 |
| Inventory | 1.3M | 0 | 0 | 0 | 0 |
| Accounts Payables | (630.9K) | 61.4K | (504.41K) | 271.78K | 146.83K |
| Other Working Capital | (2.33M) | 39.53K | 699.28K | (66.85K) | (90.9K) |
| Other Non-Cash Items | 721.63K | 67K | 31.54K | 0 | 5.05M |
| Operating Cash Flow | (14.3M) | (17.35M) | (18.09M) | (19.15M) | (27.79M) |
| Capital Expenditures | 1 | (243.26K) | (14.24K) | 0 | (13.4K) |
| Acquisitions (Net) | 0 | 243.26K | 0 | 0 | 0 |
| Purchases of Investments | 0 | (20.73M) | (29.43M) | (60.46M) | (39.09M) |
| Sales of Investments | 0 | 4.96M | 41.1M | 23.45M | 41.6M |
| Other Investing Activities | 0 | (243.26K) | 0 | 0 | 0 |
| Investing Cash Flow | 0 | (16.01M) | 11.66M | (37M) | 2.05M |
| Debt Repayment | (42.53K) | (248.91K) | 0 | 0 | 0 |
| Common Stock Issued | 41.14M | 44.14K | 8.54M | 103.48M | 108.46M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 848 | 0 | 0 | 0 | 0 |
| Financing Cash Flow | 41.09M | (204.77K) | 8.41M | 103.48M | 108.46M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 26.8M | (33.56M) | 1.98M | 47.33M | 82.73M |
| Free Cash Flow | (14.3M) | (17.59M) | (18.1M) | (19.15M) | (27.79M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$48.3M
+ D&A$60.5K
+ Stock-Based Comp$15.3M
+ Deferred Tax$0
+ Working Capital$55.9K
+ Other Non-Cash$5.0M
= Operating Cash Flow-$27.8M
- Capex-$13.4K
= Free Cash Flow-$27.8M
Analysis
FY2025 free cash flow is -$27.8M. FCF conversion is 57.6% of net income. Operating cash flow was -$27.8M, with capex of -$13.4K. The largest bridge item is Stock-Based Comp at $15.3M.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Nov 10, 2026 | |
| 10-Q | Quarterly report | Nov 10, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 21, 2026 | |
| 3 | Initial statement of beneficial ownership | Oct 21, 2026 | |
| 8-K | Current report | Oct 20, 2026 |
Does IKT generate free cash flow?
Inhibikase Therapeutics, Inc. (IKT) generated -$27.79M of free cash flow in fiscal 2025.
How much operating cash flow does IKT produce?
Operating cash flow was -$27.79M, before capital expenditures of $13,396.00.
Continue the stock analysis
Jump to another research area for this company.